



Evidence reviews

Evidence review

Published: 31 March 2022

Last updated: 12 September 2024

www.nice.org.uk

The following documents contain the evidence that was used to develop the 2026 recommendations:

- E: Initial management
 - [E1.1 Review and appendices A to C](#)
 - [E1.2 Appendix D, studies A to K](#)
 - [E1.3 Appendix D, studies L to Z](#)
 - [E2.1 Appendices E to I](#)
 - [E2.2 Appendices J and K](#)
 - [E2.3 Appendix L](#)
 - [E3](#)

- F: Subsequent management
 - [F1.1 Sections 1.1.1 to 1.1.6](#)
 - [F1.2 Sections 1.1.7 to 1.1.14](#)
 - [F2.1 Appendices A to C](#)
 - [F2.2 Appendix D1](#)
 - [F2.3 Appendix D2](#)
 - [F2.4 Appendix D3](#)
 - [F2.5 Appendix D4](#)
 - [F2.6 Appendix D5](#)
 - [F2.7 Appendix D6](#)
 - [F2.8 Appendix D7](#)
 - [F2.9 Appendix D8](#)
 - [F3](#)
 - [F4](#)
 - [F5](#)
 - [F6](#)
 - [F7](#)
 - [F8.1 \(references and appendices L to Q\)](#)
 - [F8.2 \(appendix R\)](#)
 - [F8.3 \(appendix S\)](#)
 - [F9](#)
 - [F10](#)
 - [F11](#)
 - [F12](#)
 - [F13](#)
 - [F14](#)

- Economic analyses and expert reports

- [Health inequalities report on SGLT-2 uptake](#)
- [Cost-effectiveness analysis of subsequent pharmacological therapy](#)
- [Epidemiological report on SGLT-2 uptake](#)
- [Expert testimony on transgender inclusion](#)

- Other supporting evidence
 - [Methods](#)
 - [Committee discussion](#)

Evidence for the 2022 recommendations can be found in the [evidence review on pharmacological therapies with cardiovascular and other benefits in people with type 2 diabetes](#), [continuous glucose monitoring in adults with type 2 diabetes](#) and [periodontal treatment to improve diabetic control in adults with type 1 or type 2 diabetes](#).

Evidence for the 2021 recommendations can be found in the [evidence review on SGLT2 inhibitors for people with chronic kidney disease and type 2 diabetes](#).

In 2018 we reviewed the evidence for SGLT2 inhibitors and GLP-1 mimetics, and made no new recommendations. See the [evidence review on SGLT2 inhibitors and GLP-1 mimetics](#) for more information.

Evidence for the 2009 and 2015 recommendations can be found in the 2015 full guideline on type 2 diabetes in adults, and supporting appendices:

- [2015 full guideline on type 2 diabetes in adults](#)
- [Appendix A: Guideline Development Groups & Declarations of Interest](#)
- [Appendix B: Scopes](#)
- [Appendix C: Search strategies and review protocols](#)
- [Appendix D: GRADE tables and meta-analysis result](#)
- [Appendix E: Evidence tables](#)
- [Appendix F: Full health economics report](#)
- [Appendix G: NICE guideline CG66 deleted text](#)
- [Appendix H: NICE guideline CG87 deleted text](#)
- [Appendix I: NICE guideline CG87 deleted appendix](#)
- [Appendix J: NMA results and input data](#)
- [Appendix K: WinBUGS code](#)
- [Appendix L: Excluded studies](#)

See also the 2019 surveillance report on diabetes:

- [2019 surveillance of diabetes \(NICE guidelines NG17, NG18, NG19 and NG28\)](#)
- [Appendix A1: Summary of evidence from surveillance \(NG17\)](#)
- [Appendix B1: Stakeholder consultation comments table \(NG17\)](#)
- [Appendix A2: Summary of evidence from surveillance \(NG28\)](#)
- [Appendix B2: Stakeholder consultation comments table \(NG28\)](#)
- [Appendix A3: Summary of evidence from surveillance \(NG18\)](#)
- [Appendix B3: Stakeholder consultation comments table \(NG18\)](#)
- [Appendix A4: Summary of evidence from surveillance \(NG19\)](#)
- [Appendix B4: Stakeholder consultation comments table \(NG19\)](#)